Cargando…

P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION

Detalles Bibliográficos
Autores principales: Jaeger, U., Broome, C., Go, R., Patriarca, A., Roeth, A., Chang, Q., Weedin, N., Adams, P., Cahir-McFarland, E., Kroon, H.-A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429239/
http://dx.doi.org/10.1097/01.HS9.0000849064.31599.55
_version_ 1784779377468243968
author Jaeger, U.
Broome, C.
Go, R.
Patriarca, A.
Roeth, A.
Chang, Q.
Weedin, N.
Adams, P.
Cahir-McFarland, E.
Kroon, H.-A.
author_facet Jaeger, U.
Broome, C.
Go, R.
Patriarca, A.
Roeth, A.
Chang, Q.
Weedin, N.
Adams, P.
Cahir-McFarland, E.
Kroon, H.-A.
author_sort Jaeger, U.
collection PubMed
description
format Online
Article
Text
id pubmed-9429239
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94292392022-08-31 P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION Jaeger, U. Broome, C. Go, R. Patriarca, A. Roeth, A. Chang, Q. Weedin, N. Adams, P. Cahir-McFarland, E. Kroon, H.-A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429239/ http://dx.doi.org/10.1097/01.HS9.0000849064.31599.55 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Jaeger, U.
Broome, C.
Go, R.
Patriarca, A.
Roeth, A.
Chang, Q.
Weedin, N.
Adams, P.
Cahir-McFarland, E.
Kroon, H.-A.
P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
title P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
title_full P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
title_fullStr P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
title_full_unstemmed P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
title_short P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
title_sort p1552: a phase 2, open-label study to assess safety, tolerability, and clinical effect of anx005 in patients with warm autoimmune hemolytic anemia and evidence of complement activation
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429239/
http://dx.doi.org/10.1097/01.HS9.0000849064.31599.55
work_keys_str_mv AT jaegeru p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT broomec p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT gor p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT patriarcaa p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT roetha p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT changq p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT weedinn p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT adamsp p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT cahirmcfarlande p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation
AT kroonha p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation